Sinopsis
The MDS Podcast channel was created with the ultimate goal of improving education in Parkinson's disease and other movement disorders, while keeping MDS members, other neurologists, health professionals and neuroscientists updated with novel and clinically-relevant research findings. A monthly issue of the podcast will highlight the results of an article published in the Society journals, Movement Disorders or Movement Disorders Clinical Practice, including an interview with one of the authors of the article selected.
Episodios
-
What's next? Updates in functional neuroimaging • 2025 MDS Congress
27/10/2025Developments in neuroimaging have grown a lot over the years. Dr. Thilo van Eimeren discusses biomarker development, both in tau and alpha synuclein, current research, and his hope for future successes.
-
What’s new for MSA? • 2025 MDS Congress
27/10/2025Dr. Alessandra Fanciulli discusses how the MDS criteria for the diagnosis of MSA has made an impact on the field, the status of biomarker research, and optimal targets for disease-modifying trials for MSA.
-
Highlights in ataxia • 2025 MDS Congress
27/10/2025Dr. Lauren Jackson discusses recent clinical trials, genetic updates, and interesting research in the field of ataxia.
-
Highlights for dystonia • 2025 MDS Congress
27/10/2025Prof. Susanne Schneider discusses all things dystonia. Listen as she reviews the revised MDS definition and classification system for dystonia, updates for neurodegeneration with brain iron accumulation, and the exciting future of genetic therapies.
-
Current status of functional neurosurgery • 2025 MDS Congress
27/10/2025There have been major breakthroughs in functional neurosurgery. Prof. Jill Ostrem breaks down the latest updates in the field, specifically surrounding adaptive DBS.
-
Current microbiome research for Parkinson's disease • 2025 MDS Congress
27/10/2025Prof. Paul Wilmes breaks down his #mdscongress talk discussing the recent studies on the influences of the gut microbiome on PD. He also dives into future goals and what interventions may be beneficial for PD.
-
Breaking down functional movement disorders • 2025 MDS Congress
27/10/2025Functional movement disorders (FMDs) are the most common subgroup of functional neurological disorders. Prof. Selma Aybek breaks down current trends for FMDs, controversies, and treatment preferences, including implementing an interdisciplinary team.
-
Updates in tauopathies • 2025 MDS Congress
20/10/2025Dr. Yaroslau Compta discusses how the view of co-pathologies has changed the view of many disorders, including tauopathies. He dives into the current state of clinical trials for PSP and what those results may mean for the future of biomarkers.
-
Motor rehabilitation for Parkinson’s disease • 2025 MDS Congress
20/10/2025Rehabilitation for movement disorders, like PD, has become increasingly prevalent for patient care. Prof. Alice Nieuwboer discusses how technology has shaped the field, how neurologists can support patient exercise, and what future updates she looks forward to.
-
Disease modification and Parkinson’s disease: Clinical trial design and population selection • 2025 MDS Congress
20/10/2025There have been nearly 30 years of disease modifying trials for PD, but little success. Prof. Tanya Simuni breaks down clinical trial design for a heterogenous disease like PD and discusses the future goals and importance of a biological definition.
-
Current landscape of pediatric movement disorders • 2025 MDS Congress
20/10/2025Due to genetic advancements, the pediatric movement disorder field is ever growing. Dr. Shekeeb Mohammad breaks down the current landscape of the field and how adult neurologists can advance their learning.
-
Current genetic landscape for movement disorders • 2025 MDS Congress
20/10/2025The field of genetics often moves quickly, making it a challenge to stay informed. Dr. Gerard Saranza breaks down the current landscape, new discoveries and technologies, and what changes we can expect in the upcoming years.
-
Achievements and future goals: An interview with MDS President • 2025 MDS Congress
20/10/2025Dr. Victor Fung reflects on his term as MDS President and his appreciation for the accomplishments that were achieved. He further discusses his future hopes and goals of the Society and the #mdscongress.
-
What you missed: MDS Congress Day 4
09/10/2025The last full day of the #mdscongress was full of exciting sessions and events. Dr. Laura Silveira-Moriyama shares her excitement about the keynote speaker, updates on disease modifying clinical trials, and of course, the crowd pleasing MDS Video Challenge.
-
What you missed: MDS Congress Day 3
08/10/2025Dr. Huw Morris discusses the session highlights from #mdscongress day three, which included a plenary session on protein aggregation clearance, movement disorder grand rounds, and several exciting oral platforms.
-
What you missed: MDS Congress Day 2
07/10/2025Prof. Francesca Morgante breaks down the second day of the #mdscongress which included the presidential lectures, junior awardees, and several enlightening teaching sessions.
-
What you missed: MDS Congress Day 1
06/10/2025An eventful first day of the 2025 #mdscongress has come to a close. Listen here as Dr. Davide Martino reviews the events and interesting scientific sessions for those near and far. Don’t miss out!
-
Junior Awardee: Mitochondrial and oligodendrocytic processes in MSA | Congress 2025
29/09/2025Dr. Eduardo de Pablo-Fernández interviews one of the 2025 Junior Awardees, Dr. Lydia Chougar about her work combining neuroimaging with transcriptomics and PET maps to elucidate the biological underpinnings of structural abnormalities in multiple system atrophy.
-
Junior Awardee: Identifying a subthalamic nucleus cell subtype responsible for motor benefit in a Parkinsonian mouse model | Congress 2025
29/09/2025Dr. Mitra Afshari chats with Dr. Jung Hawn Shin, one of this year’s MDS Congress Junior Awardees. Together they discuss his career path and what lead him to studying, and ultimately deciphering specific neuronal cell-types within the subthalamic nucleus (STN) that could be responsible for anti-parkinsonian motor benefits, and potentially non-motor side effects, of stimulation using optogenetic technology in Parkinsonian mice.
-
MDCP Review of the Year: Why should subacute sclerosing panencephalitis be on our radar?
22/09/2025This year’s MDCP Review Article of the Year covers the spectrum of movement disorders associated with subacute sclerosing panencephalitis (SSPE). Dr. Sarah Camargos interviews Dr. Charulata Sankhla on her team’s findings and why she believes movement disorder specialists should be aware of this measle-associated complication. Read the article.